Computational prediction of the cross‐reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV‐1 gp120

2006 ◽  
Vol 20 (11) ◽  
pp. 1762-1774 ◽  
Author(s):  
Erez M. Bublil ◽  
Sharon Yeger‐Azuz ◽  
Jonathan M. Gershoni
Keyword(s):  
Monoclonal Antibody ◽  
Computational Prediction ◽  
Neutralizing Epitope ◽  
The Cross ◽  
Hiv 1

scholarly journals Structural elements of primary CCR5-using HIV-1 gp120 proteins influencing sensitivity and resistance to the broadly neutralizing monoclonal antibody b12

Virology ◽  
2012 ◽  
Vol 432 (2) ◽  
pp. 394-404
Author(s):  
Jasminka Sterjovski ◽  
Melissa J. Churchill ◽  
Anne Ellett ◽  
Steve L. Wesselingh ◽  
Paul A. Ramsland ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Structural Elements ◽  
Neutralizing Monoclonal Antibody ◽  
Hiv 1

Generation and characterization of a human monoclonal antibody that neutralizes diverse HIV-1 isolates in vitro

AIDS ◽  
1992 ◽  
Vol 6 (1) ◽  
pp. 17-24 ◽  
Author(s):  
Douglas F. Lake ◽  
Takashi Kawamura ◽  
Takami Tomiyama ◽  
W. Edward Robinson ◽  
Yoh-ichi Matsumoto ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Human Monoclonal Antibody ◽  
Hiv 1

Characterization of a Neutralizing Monoclonal Antibody to the External Glycoprotein of HIV-1

Intervirology ◽  
1992 ◽  
Vol 34 (2) ◽  
pp. 86-93 ◽  
Author(s):  
Ranajit Pal ◽  
Fulvia di Marzo Veronese ◽  
B.C. Nair ◽  
Rukhsana Rahman ◽  
George Hoke ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Neutralizing Monoclonal Antibody ◽  
Hiv 1

scholarly journals Human immunodeficiency virus 1. Predominance of a group-specific neutralizing epitope that persists despite genetic variation.

1989 ◽  
Vol 170 (5) ◽  
pp. 1681-1695 ◽  
Author(s):  
I Berkower ◽  
G E Smith ◽  
C Giri ◽  
D Murphy
Keyword(s):  
Genetic Diversity ◽  
Human Immunodeficiency Virus ◽  
Neutralizing Antibodies ◽  
Neutralizing Epitope ◽  
Vaccine Strategy ◽  
Disease Pathogenesis ◽  
Immunodeficiency Virus ◽  
High Degree ◽  
Hiv 1 ◽  
Human Immunodeficiency Virus 1

HIV-1 is known to show a high degree of genetic diversity, which may have major implications for disease pathogenesis and prevention. If every divergent isolate represented a distinct serotype, then effective vaccination might be impossible. However, using a sensitive new plaque-forming assay for HIV-1, we have found that most infected patients make neutralizing antibodies, predominantly to a group-specific epitope shared among three highly divergent isolates. This epitope persists among divergent isolates and rarely mutates, despite the rapid overall mutation rate of HIV-1, suggesting that it may participate in an essential viral function. These findings, plus the rarity of reinfections among these patients, suggest that HIV-1 may be more susceptible to a vaccine strategy based on a group-specific neutralizing epitope than was previously suspected.

Sign in / Sign up

Export Citation Format

Share Document